HIGHLIGHTS
- who: Siri Chandana Gampa et al. from the Department of Biotechnology, Institute of Science, GITAM (Deemed to be University), Andhra Pradesh, India have published the article: Nano-TRAIL: a promising path to cancer therapy, in the Journal: (JOURNAL)
SUMMARY
TRAIL binds to TRAIL-Receptor 1/Death Receptor 4 (TRAIL-R1/DR4), TRAIL-Receptor 2/Death Receptor 5 (TRAILR2/DR5), TRAIL-Receptor 3/Decoy Receptor 1 (TRAIL-R3/DcR1), and TRAIL-Receptor 4/Decoy Receptor 2 (TRAIL-R4/DcR2). The authors elaborate on the TRAIL-induced apoptotic pathways, resistance mechanisms exhibited by cancer cells . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.